Page 10«..9101112..2030..»

Category Archives: Regenerative Medicine

The Induced Pluripotent Stem Cell (IPSC) Market Growth Is Driven By The Rising Prevalence Of Genetic Diseases – PR Newswire

Posted: August 14, 2022 at 1:52 am

The Business Research Company's induced pluripotent stem cell (IPSC) market research report expands on key drivers, trends, and growth opportunities in the market.

LONDON, Aug. 9, 2022 /PRNewswire/ --The increasing prevalence of genetic diseases is expected to drive the induced pluripotent stem cell market in the forecast period. To reveal the pathogenesis of genetic diseases, various patient-derived iPSCs were developed. These genetic abnormality-harboring iPSCs can be repaired, and the genetically repaired iPSC can be differentiated into normal-functioning cells. In the future, these patient-derived normal cells can be used in a patient-tailored therapy to replace the damaged cells due to the disease. iPSCs for various genetic diseases have been developed, such as for certain types of Parkinson's disease, spinal muscular atrophy, lentigines, electrocardiographic abnormalities, and other genetic disorders.For instance, in the case of albinism, which is a genetic disorder, an estimated 1 in 20,000 people worldwide are born with oculocutaneous albinism. Also, nearly one million people were living with Parkinson's disease (PD) in the U.S. by 2020.

The global induced pluripotent stem cell (iPSC) market size is expected to grow from $ 2.43 billion in 2021 to $ 2.64 billion in 2022 at a compound annual growth rate (CAGR) of 8.6%. The induced pluripotent stem cell (iPSC) technology market is expected to reach $ 3.57 billion in 2026 at a CAGR of 7.8%.

Request a free sample of the Induced Pluripotent Stem Cell (IPSC) Market Report

Induced Pluripotent Stem Cells Market Overview

The induced pluripotent stem cell (iPSC) market consists of sales of induced pluripotent stem cells and related services. Induced pluripotent stem cells are the regenerated form of stem cells, which are produced from an existing adult cell, such as hepatocytes, fibroblasts, keratinocytes, and neurons. The various applications include academic research, drug development and discovery, toxicity screening, and regenerative medicine and are used in several sectors such as hospitals and research laboratories.

Induced Pluripotent Stem Cells Are Increasingly Being Used To Treat Type 1 Diabetes

As per the induced pluripotent stem cell (iPSC) market report, players in the industry are extensively developing pluripotent cells to treat type 1 diabetes. Cellular therapy has recently been started for type 1 diabetes (T1D) to replace islet cells, which are insulin-producing cells that are lost in T1D patients. These problems could be at least partially resolved by producing pancreatic islet cells from PSCs, and significant advancements have been made by imitating how the human pancreas naturally develops. Recently, two biotech companies, Semma Therapeutics and Viacyte, produced cells that were found to be capable of functional insulin secretion upon exposure to high-glucose or high-potassium stimuli.

In 2021, Fujifilm Holdings Corporation Held The Largest Market Share

Fujifilm Holdings Corporation was the largest competitor in the induced pluripotent stem cell market in 2021, with a 10.46% share of the market. FUJIFILM Cellular Dynamics's growth strategy focuses on strengthening its cell therapy business through expanding its operational capabilities. For instance, in March 2020, the company began the operation of its new cGMP-compliant-1 iPSC production at the Innovation Facility for Advanced Cell Therapy (i-FACT). The new facility is involved in manufacturing and developing induced pluripotent stem cells for therapeutic applications.

See more on the Induced Pluripotent Stem Cell (IPSC) Market Report

Check out similar market reports:

Stem Cell Therapy Global Market Report 2022 By Type (Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy), By Cell Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells), By Application (Musculoskeletal Disorders, Wounds And Injuries, Cancer, Autoimmune Disorders), By End-User (Hospitals, Clinics) Market Size, Trends, And Global Forecast 2022-2026

Regenerative Medicine For Cartilage Global Market Report 2022 By Treatment Modality (Cell-Based, Non-Cell-Based), By Treatment Type (Palliative, Intrinsic Repair Stimulus), By Site ( Knee Cartilage Repair, Ribs), By Application (Hyaline Cartilage Repair And Regeneration, Elastic Cartilage Repair And Regeneration, Fibrous Cartilage Repair And Regeneration), By End-Use (Ambulatory Surgical Centers, Hospitals & Clinics, Surgical Centers ) Market Size, Trends, And Global Forecast 2022-2026

Gene Editing Global Market Report 2022 By Technology (CRISPR, TALEN, ZFN), By End Users (Biotechnology, Pharmaceutical, Contract Research Organization), By Application (Animal Genetic Engineering, Plant Genetic Engineering, Cell Line Engineering) Market Size, Trends, And Global Forecast 2022-2026

Interested to know more about The Business Research Company?

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally, it has strategy enablement specialists in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

The World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

Contact Information:The Business Research CompanyEurope: +44 207 1930 708Asia: +91 8897263534Americas: +1 315 623 0293Email: [emailprotected]LinkedIn: https://in.linkedin.com/company/the-business-research-companyTwitter: https://twitter.com/tbrc_infoYouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQBlog: http://blog.tbrc.info/

Logo: https://mma.prnewswire.com/media/1751581/tbrc_logo.jpg

SOURCE The Business Research Company

Read more:
The Induced Pluripotent Stem Cell (IPSC) Market Growth Is Driven By The Rising Prevalence Of Genetic Diseases - PR Newswire

Posted in Regenerative Medicine | Comments Off on The Induced Pluripotent Stem Cell (IPSC) Market Growth Is Driven By The Rising Prevalence Of Genetic Diseases – PR Newswire

Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte on Chronic Obstructive Pulmonary Disease Model Compared to Conventional…

Posted: August 14, 2022 at 1:52 am

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Phase III Clinical Stage Company Demonstrates Superior Efficacy of Proprietary Stem Cell Apoptotic Body Based Drug

ELK CITY, Idaho--(BUSINESS WIRE)--Therapeutic Solutions International announced today new data demonstrating superior effects of the Companys ApoptoCyte procedure treated JadiCell product compared to other stem cells in treating an animal model of Chronic Obstructive Pulmonary Disease (COPD).

In a series of experiments, mice were administered the enzyme elastase to mimic COPD. It was shown that untreated JadiCell stem cells, as well as stem cells from sources conventionally utilized, specifically fat and bone marrow, had some therapeutic activity including reduction of inflammation, stimulation of regenerative growth factors, and preservation of alveoli structure1. All cell types had improved therapeutic activity when processed using the ApoptoCyte procedure, with JadiCell possessing the highest activity.

In May of this year we announced and filed a patent on the ApoptoCyte procedure which involves the induction of cellular suicide in the stem cell, extraction of small vesicles called apoptotic bodies and co-administration with specific drugs such as certain histone deacetylase (HDAC) inhibitors. Leveraging this technology, we have filed a new patent on COPD which contains the data disclosed today, said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of both patents. The demonstration that the ApoptoCyte Procedure is applicable to COPD, which is one of the major causes of death in the world, is extremely exciting.

The Company possesses IND #28508 for using non-modified JadiCells for COPD, however the clinical trial is expected to initiate following further discussions between the Company and the FDA. Additionally, the Company currently is running a Phase III clinical trial using JadiCells for treatment of advanced COVID-19 infection.

COPD represents a significant unmet medical need for which no curative approaches exist, said Timothy Dixon, President, and CEO of the Company and co-inventor of the patents. We are grateful to have a team of cellular and COPD experts who have assisted us in creating what we believe is a first in class approach to treating COPD. We hope to continue exploring the applicability of the ApoptoCyte Procedure in other therapeutics in the regenerative medicine space.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is http://www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Announces ApoptoCyte Procedure for Enhancing Stem Cell Activity | BioSpace

View source version on businesswire.com: https://www.businesswire.com/news/home/20220812005201/en/

Timothy G. Dixon[emailprotected]

Source: Therapeutic Solutions International, Inc.

Follow this link:
Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte on Chronic Obstructive Pulmonary Disease Model Compared to Conventional...

Posted in Regenerative Medicine | Comments Off on Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte on Chronic Obstructive Pulmonary Disease Model Compared to Conventional…

Ethical perils lie ahead after the creation of ‘synthetic embryos’ – MercatorNet

Posted: August 14, 2022 at 1:52 am

Israeli scientists have created the worlds first synthetic embryos. They used mouse stem cells to create embryos, nurtured them in an artificial womb, and grew them for 8 days roughly the equivalent of three weeks of a human pregnancy.

Their research, which was published in the journal Cell last week, is being acclaimed by scientists as a ground-breaking development. Inside the tiny mouse embryos, the researchers can see organs developing. We view the embryo as the best 3D bio printer, says Jacob Hanna, a biologist at the Weizmann Institute of Science, told MIT Technology Review. Its the best entity to make organs and proper tissue.

The mouse embryos developed beating hearts, flowing blood, intestinal tracts and cranial folds in the brain even though they were created from scratch in a Petri dish.

This experiment has huge implications, says Bernard Siegel, of the World Stem Cell Summit, a group which lobbies for regenerative medicine. One wonders what mammal could be next in line.

All going well, the next mammal is going to be homo sapiens.

Dr Hannas ambitions are immense. The ultimate goal of his start-up company, Renewal Bio, is to make humanity younger and healthier by leveraging the power of the new stem cell technology to solve ailments such as infertility, genetic diseases, and longevity.

He believes that there will be a huge market for products derived from synthetic human embryos.

Since the turn of the century, developed nations have seen a clear trend: declining birth rates and fast aging populations. With significant socioeconomic implications, this trend threatens to upend health systems, retirement programs, and workforces across the globe. At the beginning of life, this is shown by a 5-10% increase in infertility treatments by U.S. couples each year. Towards the end of life, these issues are manifesting in fast-aging populations that balloon healthcare costs. In the U.S., the aging population is driving national health expenditures to increase at a rate of 5.5% per year, and are expected to reach more than $6 trillion annually by 2027.

The vision of the company is Can we use these organized embryo entities that have early organs to get cells that can be used for transplantation? We view it as perhaps a universal starting point, Dr Hanna says.

What he has in mind is projects like rebooting the immune system for the elderly by creating blood from an embryo. Or growing a female embryo until the gonads form and the eggs can be harvested. In other words, Dr Hanna and his colleagues want to strip-mine human embryos which have been custom-made for their clients.

They also claim that their method of producing synthetic embryos creates the placenta and yolk sac surrounding the embryo. This suggests that perhaps a baby could reach full term in an artificial womb with no need for a mother at all.

But would these synthetic embryos really be human? Hanna dismisses the idea. We are not trying to make human beings. That is not what we are trying to do, he told MIT Technology Review. To call a day-40 embryo a mini-me is just not true.

However, Dr Hanna is not a philosopher. He is just a talented technician tinkering with biological structures. Whether or not it is human is not his to decide. Even though the embryo has not been conceived naturally, it might grow into a human being if it were transferred into a womb.

At the moment scientists quoted in the media are insisting that synthetic embryos are definitely not embryos. As Australian stem cell scientist Megan Munsie wrote in The Conversation: They replicate only some aspects of development, but not fully reproduce the cellular architecture and developmental potential of embryos derived after fertilisation of eggs by sperm so-called natural embryos.

But even if this is true, Dr Hannas ultimate goal seems to be to create synthetic embryos which are as close as possible to natural embryos. If they are not human initially, might they become human later on, as the field advances?

With so many unknowns, the need for regulation of this new technology is urgent. And the ones writing the law should not be the same entrepreneurs who stand to become billionaires if their dreams come true. If the brief history of stem cell science has taught us anything, it is that scientists lust for power always outruns their interest in ethics.

Read more:
Ethical perils lie ahead after the creation of 'synthetic embryos' - MercatorNet

Posted in Regenerative Medicine | Comments Off on Ethical perils lie ahead after the creation of ‘synthetic embryos’ – MercatorNet

Aesthetics Biomedical Inc. Announces Issuance of its Third U.S. Patent for Biological Preserving Composition and Methods of Use for its SoME Skincare…

Posted: August 14, 2022 at 1:52 am

This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedicals product portfolio, Shaun Wootten, Director of Innovation and Design.

PHOENIX (PRWEB) August 10, 2022

Aesthetics Biomedical Inc (ABM), a leader in regenerative medicine and advanced aesthetics committed to the development and distribution of breakthrough, novel, and personalized aesthetic devices and products announces the issuance of its third US patent for Biological Preserving Composition and Methods of Use from the United States Patent Trademark Office. The newly issued [third] patent continues the protection of its innovation in the proprietary topical compositions of its SoME Skincare product which combines with physician infused biologics and presents the future of personalized skincare.

Founder & Chief Executive Officer, MaryAnn Guerra says of the issuance Once again, I am excited to see that Aesthetics Biomedicals innovations have been validated by the issuance of a new patent, further strengthening our SoME Skincare brand and patent portfolio. Our SoME Skincare product line will be expanded to fully utilize the broader patent coverage, under the leadership of our Director of Innovation & Design, Shaun Wootten.

SoME Skincare, medically dispensed through professional offices, with its unique technology platform combines the bodys own regenerative cytokines within skincare. Proven in skin renewal and regeneration, SoME Skincare is clinically shown to improve both visual and cellular facial aging. This latest, additional patent for preserving biologics marks a paradigm shift for skincare and adds additional protection to Aesthetics Biomedicals product portfolio, said Shaun Wootten, Director of Innovation and Design. This is Aesthetics Biomedicals broadest patent yet on the matter and cements the ingenuity of our Center of Aesthetic Innovation.

The growth factors, derived from Platelet Rich Plasma [PRP] infused within its advanced formula signals the biochemical receptors on the cell surface to stimulate new collagen and new elastin critical for regeneration and repair of photodamaged skin to produce a personalized, autologous skincare treatment. Aesthetics Biomedical Inc. is continuing to build its pipeline of regenerative products with a focus on skin, hair, and nail personalized products. The patents cover multiple delivery systems including, gel, cream, ointment, and spray. This is coupled with the PRP serving as a rich source of exosomes that provide a natural comprehensive means for regeneration. According to Lawrence A Rheins PhD, Chief Scientific Officer, The additional patent protection offered for SoME Skincare, will continue to provide Aesthetics Biomedical with a unique technology platform consisting of stabilized platelet rich plasma, permitting Aesthetics Biomedical to develop a multitude of topical products for various skin conditions including facial anti-aging.

ABOUT AESTHETICS BIOMEDICAL: Aesthetics Biomedical Inc., headquartered in Phoenix, Ariz., is committed to the development and distribution of novel aesthetic devices, products, and services in the global market. Aesthetics Biomedicals innovation center is a leader in breakthrough technologies and combination therapies for its clients, physician network, and the aesthetic arena, creating novel and unique patient experiences that benefit from ongoing research, approved clinical indications for use, as well as a personalized approach designed for consumer benefit. For more information, please visit [AestheticsBiomedical.com.

Share article on social media or email:

View post:
Aesthetics Biomedical Inc. Announces Issuance of its Third U.S. Patent for Biological Preserving Composition and Methods of Use for its SoME Skincare...

Posted in Regenerative Medicine | Comments Off on Aesthetics Biomedical Inc. Announces Issuance of its Third U.S. Patent for Biological Preserving Composition and Methods of Use for its SoME Skincare…

Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID – PR…

Posted: August 14, 2022 at 1:52 am

SEOUL, South Korea, Aug. 10, 2022 /PRNewswire/ --Panacell Biotech Co., Ltd. said that NK cells, exosomes, and brown adipose-derived stem cells are effective to treat patients with long COVID conditions, or post COVID-19 conditions, as well as those with terminal illness.

Seung-Ho Choi, CEO of Panacell Biotech

Panacell Biotech is South Korea's research institute specializing in advanced regenerative medical cell therapy using adipose-derived stem cells (ADSC).

The company announced on August 10 that it will soon conduct those cells' toxicity tests through clinical trials and laboratory animals.

Currently, in South Korea, there are guidelines for plasma treatment that administers plasma from patients who have recovered from COVID-19 to other patients. Although there already exist COVID-19 treatments, such as Paxrovid, a clear therapeutic effect has not been confirmed yet.

There are over 60 long COVID conditions, including decreased libido and hair loss.

According to the Mayo Clinic, a nonprofit American academic medical center, "A whopping one in four people aged 65 or above suffer from aftereffects of COVID-19"

The Guardian also reported that people with long COVID often experience and an "extremely broad" variety of symptoms, including less well-known side effects such as amnesia, and an inability to perform familiar movements or commands."

According to the TIME magazine said about four million people or 2.4% of the U.S. employed population have reduced ability to work because of Long COVID.

Associate Professor Gwenalle Douaud at the Nuffield Department of Clinical Neurosciences (NDCN), University of Oxford, and her team observed a "greater reduction in grey matter thickness and tissue contract in the orbitofrontal cortex and parahippocampal gyrus" and "greater changes in markers of tissue damage in regions that are functionally connected to primary olfactory cortex." While the long-term effects of COVID-19 on smell remain inconclusive, the study suggests a possible connection between brain changes by COVID-19 and memory.

However, there have been many clinical results in which the coronavirus causes inflammation in various organs, including the respiratory system, and chronic symptoms persist.

While research on a treatment for COVID-19 is underway around the world, Chinese researchers said they are researching ways to treat COVID-19 patients using stem cells.

Sun Yanrong, Deputy Director of China Biotechnology Development Center, asserted, "We are continuing to monitor the treatment using stem cells. In Wuhan, over 200 patients have already been treated with stem cells."

He continued explaining, "The clinical treatment results show that the stem cell therapy has good safety and has also been confirmed to have a therapeutic effect. It was also effective in recovering the lungs."

Seung-Ho Choi, CEO of Panacell Biotech, affirmed, "We expect that this clinical trial will reveal therapeutic effects of stem cell therapy along with these treatments."

Panacell Biotech is a leading bio institute in advanced regenerative medicine and cell therapy, widely recognized for its contributions to the development of biotechnology by researching stem cell culture and cell banking, focusing on the development of treatments for various cancers and incurable diseases.

The Ministry of Food and Drug Safety of South Korea approved Panacell Biotech on April 1 this year as one of the 21 licensed cell treatment facilities.

It received the K-ESG Management Innovation Award in June 2022, and is scheduled to receive the 2022 Global Clean Environment Award in the healthcare category in this upcoming October 18.

View original content to download multimedia:https://www.prnewswire.com/news-releases/panacell-biotech-to-conduct-toxicity-tests-for-nk-cells-exosomes-and-brown-adipose-derived-stem-cells-to-treat-patients-with-long-covid-301603403.html

Source: Panacell Biotech Co., Ltd.

Read the original:
Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID - PR...

Posted in Regenerative Medicine | Comments Off on Panacell Biotech to conduct toxicity tests for NK cells, exosomes, and brown adipose-derived stem cells to treat patients with long COVID – PR…

PAINWeek 2022 Announces the Return of the ASIPP and Interventional Pain Management Tracks – PR Web

Posted: August 14, 2022 at 1:52 am

The PAINWeek National Conference, September 6-9

MONTCLAIR, N.J. (PRWEB) August 11, 2022

The statistics are alarming: At least a fifth of the US population has chronic pain.[1] Costs to society, ranging from direct costs to lost work, is over $630 billion a year.[2] Something needs to change, and education will help. At the PAINWeek National Conference, September 6-9 at The Cosmopolitan of Las Vegas, attendees will experience stellar pain management education, including the ASIPPAmerican Society of Interventional Pain Physiciansand the Interventional Pain Management Tracks.

The ASIPP Track will include Nick Knezevic, MD, PhD, presenting Atomic Secrets: Regenerative Medicine in Managing Chronic Pain. He commented, ASIPP has a long-standing relationship with PAINWeek. Together, theyve organized a series of lectures with ASIPP key leaders as speakers to help explain the importance of interventional pain management procedures in managing pain conditions.

The ASIPP Track will also feature the following courses and presenters:

Sean Li, MD, who will present during the Interventional Pain Management Track, stated, PAINWeek has always been one of my favorite meetings because of its diversity and inclusion: it is the only meeting where I can join clinicians from all specialties who treat pain patients. Dr. Li's sessions: The Petrified Forest: Sacroiliac Joint Dysfunction and Treatment Update; and When Stars Align: The New Era of Peripheral Nerve Stimulation. He continued, Attendees will experience an emersion of emotional and intellectual experiences into the world of pain management. Dont miss out!

Johnathan Goree, MD, who will co-present East v. West: Who Should Hold the Needle First?, commented, I am excited to again take part in PAINWeek, this time discussing back pain and Whats next? I will debate Carrie Hyde, MD, a physician medical acupuncturist, and discuss our approaches to the low back pain patient, treatment philosophies, cost benefit analysis. Wholl win the debate? Both attendees and patients!

The Interventional Pain Management Track will also feature:

PAINWeek will present over 75 CME/CE credit hours in tracks such as Behavioral Pain Management, Chronic Pain Syndromes, Health Coaching, Integrative Pain Management, Medical/Legal, Neurology, Physical Therapy, Pharmacotherapy, and Psychedelics. Master Classes, Special Interest Sessions, and sponsored courses complement the agenda, along with tracks presented by the International Pelvic Pain Society.

For more information, click PAINWeek or go to painweek.org.

Dr. Goree: Associate Professor and Director of Chronic Pain Division, University of Arkansas for Medical Sciences, Little Rock. Dr. Knezevic: Clinical Professor of Anesthesiology & Surgery, College of Medicine, University of Illinois, Chicago. Dr. Li: Regional Medical Director, National Spine and Pain Centers, Lincroft, New Jersey.

PAINWeek accreditation provided by Global Education Group:

Global Education Group focuses on producing partnership-based CME for healthcare practitioners. The Global team works with a select group of medical education companies, associations, academic institutions, and healthcare facilities to develop and accredit live healthcare conferences and workshops as well as online activities. With each partnership or joint providership, Global brings accreditation expertise, project management excellence and grant funding intelligence. Based in Littleton, Colo., Global has accreditation with commendation from the ACCME and accredited with distinction from the ANCC. Global also holds accreditations to offer continuing education for nurse practitioners, pharmacists, dietitians, dentists, and psychologists. Global is a division of Ultimate Medical Academy.

1. National Center for Health Statistics, National Health Interview Survey, 2019.2. https://nationalpain.org/fast-facts-about-pain

###

Share article on social media or email:

Read this article:
PAINWeek 2022 Announces the Return of the ASIPP and Interventional Pain Management Tracks - PR Web

Posted in Regenerative Medicine | Comments Off on PAINWeek 2022 Announces the Return of the ASIPP and Interventional Pain Management Tracks – PR Web

What Is Minoxidil? A Complete Guide to the Product – Mane Addicts

Posted: August 14, 2022 at 1:52 am

Minoxidil, or the active ingredient in Rogaine, has been billed as a miracle cure for hair loss. But what is it, really? And more importantly, who does it help? Hair thinning can be a painful process so we take special notice when we find something that can stop or reverse it. While weve tried the natural route (hello, rosemary oil) its not every day we find an actually clinically proven solution to hair loss. So, to learn more about this ingredient, we checked in with an expert for a guide on what it is, its side effects, benefits, and how to use it.

About the Expert

Azza Halim, M.D., is a board-certified aesthetic medicine, anti-aging, and regenerative medicine physician.

Minoxidil was originally developed to lower blood pressure in the 1960s, with a happy side effect being hair growth. It was then formulated into a topical treatment to treat hair loss in men as Rogaine, followed by a female-specific product. Board-certified physician Azza Halim, M.D. explains, It is a vasodilator medicationthat canbe taken as a pill or applied topically. This means it expandsbloodvesselsto increase flow, circulation, and add nutrients to the follicles, she continues.

The main benefit of minoxidil is restoring haireven a little bit back can be a huge confidence booster. According to Dr. Halim, minoxidil may expand the hair follicles, especially those that shrunk over time or in response to hormonal changes, which translates to more sustained growth. It also prolongs the growth phase of the hair cycle, aka the anagen phase, she notes. Minoxidil can increase hair thickness, density, and treat hair disorders like androgenetic alopecia and female pattern hair loss.

Ideal candidates are those in early stages of hair loss or thinning, says Dr. Halim. All hair types can take minoxidil, though it may be less effective on women with natural hair who have scarring from alopecia. Pregnant women cant take minoxidil, and it isnt safe for nursing mothers either. It can cause irritation when mixed with hair dye, though it can be used on color-treated hair.

As with everything there are pros and cons/side effects, Dr. Halim tells us. Side effects include scalp dryness, irritation, low blood pressure, allergic reaction, and rarelybut it is possibleto trigger interim hair loss before stimulating hair growth. Other side effects include unwanted hair growth, lightheadedness, and scalp irritation.

Minoxidil must be applied topically twice a day, says Dr. Halim. Dont expect instant gratification, however, as results take three to four months. If you stop minoxidil, be warned that hair will revert to the thickness it would have been if you didnt take it at all, not where it was when you startedthis can be a shocker. The downside is once discontinued, hair then reverts to baseline and new growth will be lost within few months, therefore, it needs maintained use, she continues. Minoxidil giveth and minoxidil taketh away.

This 2% solution is clinically proven to help fight hair loss by activating hair follicles at the scalp and extending your hairs natural growth cycle. You can even subscribe to get this product delivered to your door every month so you wont miss out on a treatment.

With a 4.2 star review from nearly 200 reviews on Ulta, its no wonder this treatment is recommended by so many. Yes, it does take about three to six months for results to show, but once they do, youll realize why it was worth the wait.

A 5% topical treatment, Rogaines four-month supply will take you to the first stages of hair regrowth.

Promote hair growth with minoxidil and refresh follicles naturally with biotin, thanks to this hair growth oil. Youll be happy to know its free of parabens, gluten, sulfates, and any other nasty ingredients that may irritate your scalp. Translation? You likely wont experience any minoxidil side effects.

Minoxidil meets DHT blocker Finasteride and Spironolactone, which slows the production of hair loss-causing hormones. People who have used this treatment have said they noticed hair regrowth in as little as one month.

Original post:
What Is Minoxidil? A Complete Guide to the Product - Mane Addicts

Posted in Regenerative Medicine | Comments Off on What Is Minoxidil? A Complete Guide to the Product – Mane Addicts

CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors – Business Wire

Posted: August 14, 2022 at 1:52 am

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appointment of Dr. Gail K. Naughton to its Board of Directors.

Dr. Naughton has been a pioneer in the field of regenerative medicine for over 35 years. She was the founder of Advanced Tissue Sciences (NASDAQ:ATIS) where she oversaw the design and development of the worlds first up-scaled manufacturing facility for cell-based products, established corporate development and marketing partnerships with companies including Smith & Nephew, Medtronic, and Inamed Corporation, was pivotal in raising over $350 million from the public market and corporate partnerships, and brought four human cell-based products from concept through FDA approval and market launch. She founded Histogen (NASDAQ:HSTO) in 2007 and holds more than 125 U.S. and foreign patents and has been extensively published in the field. Dr. Naughton served as Dean of the College of Business Administration at San Diego State University from 2002 until 2011 where she helped to make SDSU the first US campus to establish a Ph.D./MBA in life sciences. In 2000, Dr. Naughton received the 27th Annual National Inventor of the Year award by the Intellectual Property Owners Association in honor of her pioneering work in the field of tissue engineering and regenerative medicine. Dr. Naughton received her Ph.D. and M.S. from NYU Medical Center and an MBA from UCLA. She currently sits on the Board of directors of Therapeutics MD (NASDAQ: TXMD) and is the Chair of the Board of the La Jolla Institute for Immunology.

A highly accomplished visionary in biotechnology, Dr. Naughton has brought several FDA approved products to market, and we are very pleased to welcome her to our board. Her unparalleled expertise will be very helpful to CEL-SCI, stated CEL-SCI CEO Geert Kersten.

Dr. Naughton commented, Based on the results of the largest study of its kind, Multikine can significantly improve outcomes for patients with newly diagnosed head and neck cancer. CEL-SCIs management team and board have been tenacious in advancing an immune therapy that can have the greatest beneficial impact on patientswhen they are first diagnosed with cancer. I look forward to contributing my guidance as the company transitions through regulatory approval and into delivering treatments that can help extend patient lives.

About CEL-SCI Corporation

CEL-SCI believes that boosting a patients immune system while it is still intact should provide the greatest possible impact on survival. Therefore, in the Phase 3 study CEL-SCI treated patients who are newly diagnosed with advanced primary squamous cell carcinoma of the head and neck with the investigational product Multikine* first, BEFORE they received surgery and radiotherapy or surgery plus concurrent radiochemotherapy (the current standard of care for these patients). This approach is unique. Most other cancer immunotherapies are administered only after conventional therapies have been tried and/or failed. Multikine (Leukocyte Interleukin, Injection) received Orphan Drug designation from the FDA for neoadjuvant therapy in patients with squamous cell carcinoma (cancer) of the head and neck. CEL-SCI believes that this Phase 3 study is the largest Phase 3 study in the world for the treatment of advanced primary head and neck cancer.

Multikine is designed to help the immune system see the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. The Phase 3 study was started in early 2011 and was fully enrolled with 928 patients in September 2016. To prove an overall survival benefit, the study required CEL-SCI to wait until at least 298 (deaths) events had occurred among the two main comparator groups. The study results announced in June 2021 showed excellent survival benefit for those patients who received Multikine treatment regimen plus surgery and radiation. When chemotherapy was added to radiotherapy following surgery the survival benefit was negated.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such statements include, but are not limited to, statements about the terms, expected proceeds, use of proceeds and closing of the offering. Factors that could cause or contribute to such differences include an inability to duplicate the clinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K for the year ended September 30, 2021. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

* Multikine (Leukocyte Interleukin, Injection) is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with the Company's future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use.

More:
CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors - Business Wire

Posted in Regenerative Medicine | Comments Off on CEL-SCI Appoints Dr. Gail Naughton to Its Board of Directors – Business Wire

Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia – GlobeNewswire

Posted: August 5, 2022 at 1:58 am

LAS VEGAS, NV, Aug. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Meso Numismatics, Inc. (Meso Numismatics or the Company) (MSSV), a technology company specializing in Biotech and Numismatics, is pleased to announce additional global expansion by opening stem cell therapy and regenerative medicine facilities in Indonesia. The new facilities emphasize Global Stem Cells Group's objective of introducing its therapies and technology to meet market demands in populous parts of the world.

In partnership with the Dr. Yanti Aesthetic Clinics, which currently has 6 branches across Indonesia, this latest GSCG expansion will promote high standards of service in regenerative medicine across the country. As part of this effort, through GSCG the International Society for Stem Cells Applications (ISSCA) has granted Dr. Yanti Aesthetic Clinics membership and use of its brand, products, therapies, and training on how to apply stem cell therapies.

This new partnership seeks to expand the Global Stem Cells Group (GSCG) brand and create centers of excellence in cell therapy to meet the high demand within the vast Asian markets, said David Christensen, CEO of MSSV. GSCG is rapidly expanding its global operations as it seeks to become a significant player in the lucrative regenerative medicine industry. To achieve our expansion plans, our organization is partnering with healthcare providers specializing in regenerative medicine with at least five years of experience in the healthcare sector.

Video: https://youtu.be/T2CFjsps9qk

The vision behind the effort.

The Indonesia addition is the latest part of an expanding medical network of partners, and it will formalize and strengthen ties, establishing a global center of excellence to guarantee that we effectively use the underlying basic stem cell technology for medical conditions, where traditional therapeutic approaches seem to have failed. This is consistent with GSCG's overall strategy for developing regenerative medicine through data-driven studies, disease modeling, and cell-based therapeutics.

The Dr. Yanti Aesthetic Clinic is a key partnership because it provides the organizational and physical infrastructure needed to disseminate need-based stem cell locally. And Global Stem Cells Group's outstanding cell and stem cell biology and disease pathophysiology give an edge to patients for which they are prescribed.

The opening in Indonesia also presents the perfect opportunity to translate breakthrough therapies from basic discoveries to useful products by drawing upon the skills and local knowledge promoted within Dr. Yanti Aesthetic Clinics.

GSCG group managing director, Benito Novas, provided a clear description of the new strategic direction and objectives. "Our goal is to make regenerative medicine benefits a reality for both doctors and patients all around the world. We recently launched a very similar effort in Pakistan. Additional announcements are planned in the near future as we attempt to expand our presence." Meso Numismatics and Global Stem Cells Group Expand its Global Footprint

The current market outlook.

Stem cell therapy is striving to become an increasingly effective clinical solution to treat conditions that traditional or mainstream medicine offers only within palliative care and pain management. Patients all over the world are searching for a natural regenerative alternative without the potential risks and side effects sometimes associated with mainstream pharmaceuticals. With the opening of each new treatment center in populous regions such as Indonesia, GSCG is working to help stem cell therapy and regenerative medicine to eventually move from alternative and elective procedures to mainstream protocols.

This new clinic effort will play a significant role in the development of regenerative medicine in Indonesia and indeed the rest of the world by adding yet another opportunity for continuous improvement through research and development, Christensen continued. By adding busy clinics in population centers, we plan to consistently generate high volumes of reliable clinical data to assist us with the development and refinement of even more medicines and treatments.

About Dr. Yanti Aesthetic Clinics

Dr. Yanti Aesthetic Clinics is a premier cosmetic and aesthetics clinic based in Kelapa Gading, Jakarta Utara. Since its inception in 2004 in Surabaya by Dr. Khoe Yanti Khusmiran, the clinic has expanded to over 6 branches throughout Indonesia. Dr. Yanti clinics provide a range of skin and body enhancement treatments through minimally invasive and non-invasive procedures the expertise of which are a natural fit for the addition of a variety of stem cell therapies.

"Indonesians have a growing need for the latest medical technology that is reliable, potent, has reduced side effects, and leverages the bodys own healing biochemistry to resolve injury and aging, said Dr. Yanti. We are honored to be a part of GSCG, which has a proven 10-year track record in the market with a strong and growing international reputation. This new partnership is expected to create a wide variety of custom treatment options we can offer our patients and treat injury and illness in ways we could not before.

The newly formed partnership will deliver revolutionary medicines through Dr. Yanti clinics to assist patients in avoiding permanent harm and live a healthier life, while changing the paradigm from asymptomatic treatments to cures that may improve and restore quality of life.

More about Global Stem Cells Group

GSCG delivers leadership in regenerative medicine research, patient applications, and training through our strategic global networks. We endeavor to enable physicians to treat otherwise incurable diseases using stem cell therapy and to improve the quality of life and care across the world.

For this reason, GSCG works with innovative, next-generation therapy providers like Dr. Yanti Aesthetic Clinics to give access to one-of-a-kind holistic and safe treatment options.

More information regarding this transaction and the Global Stem Cells Group may be found at GSCG.

This press release should be read in conjunction with all other filings on http://www.sec.gov

For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com

About Meso Numismatics: Meso Numismatics, Corp is an emerging Biotechnology and numismatic technology company. The Company has quickly become the central hub for rare, exquisite, and valuable inventory for not only the Meso region, but for exceptional items from around the world.

Meso has now added Biotechnology to its portfolio and will continue to grow the company in this new direction. With the Company's breadth of business experience and technology team, the Company will continue to help companies grow.

Forward-Looking Statements

Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words plan, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Meso Numismatics, Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Meso Numismatics, Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

For further information, please contact:investor.relations@mssvinc.com Telephone: (800) 956-3935

Read more:
Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia - GlobeNewswire

Posted in Regenerative Medicine | Comments Off on Global Stem Cells Group Expands Its Stem Cell Therapy and Regenerative Medicine Centers to Indonesia – GlobeNewswire

QC Kinetix (Wilmington) is the Go-to Regenerative Medicine Clinic for Back Pain and Sports Injury Treatment – Yahoo Finance

Posted: August 5, 2022 at 1:58 am

Wilmington, NC - (NewMediaWire) - August 3, 2022 - Chronic pain conditions can have severe adverse effects on the quality of one's life, from forcing them to contend with debilitating, life-altering, incessant pains to robbing them of their independence. Despite its significant advances in recent years, conventional medicine is yet to offer conclusive solutions for many such conditions, leaving many patients at a loss regarding their options. Luckily, the field of regenerative medicine, a specialty area of QC Kinetix (Wilmington), offers a better alternative to conventional medicine in combating many chronic pain conditions with evidence-based results. The pain control clinic offers patients a way out from aggravating pain and a good shot at regaining complete control of lost or limited body functions such as mobility.

A brainchild of years of painstaking research and innovative insight, the clinic's regenerative therapies take advantage of the human body's natural self-healing processes to restore and heal. Athletes who have suffered sports injuries and are looking for a way to get back in the game can rely on the clinic's sports medicine treatments to help. The treatment providers at QC Kinetix (Wilmington) use natural sports medicine treatments on their patients with renewed hope for a full recovery.

Before administering the sports medicine treatments, the medical providers begin each process with a complete diagnosis, extensive on-site medical examinations, and medical history deep-dives to establish each patient's suitability for regenerative treatment, including athletes. This initial step is crucial in helping identify individuals, such as cancer patients, for whom regenerative medicine is unsuitable and potentially harmful.

Upon passing QC Kinetix (Wilmington)'s mandatory pre-screening process, patients can begin their journey to wellness immediately. The clinic's medical providers develop individualized treatment plans to fast-track each patient's recovery process. They locally administer biologic agents directly to the affected body parts using minimally invasive procedures that, unlike surgeries, leave no wounds that take time to heal. These agents trigger, stimulate, and sustain a restorative immunity process that addresses underlying issues causing chronic pain instead of focusing on alleviating their symptoms.

Going by many patients' first-hand accounts about their experiences at QC Kinetix (Wilmington), regenerative therapies are effective against many chronic pain conditions. The treatments can be used for joint, hip, knee, elbow, shoulder, wrist, toe, heel, thigh, finger, and lower & upper back pain treatments. For back pain treatment in Wilmington, patients who have undergone the process using regenerative medicine have admitted realizing significant progress after their first few sessions, with some reporting full recovery in a few months. Rather than undergoing invasive surgeries, many patients have chosen the natural way of back pain treatment using regenerative medicine. The back pain treatment at the pain control clinic focuses on the point of injury or pain to accelerate the natural healing process, leading to long-lasting pain relief.

While analgesics can help alleviate pain, they are fleeting remedies at best since they focus on symptoms instead of treating their causes at the source. Therefore, patients who prefer this route can never stop using such medications without experiencing a resurgence of their pains. With prolonged usage comes many associated side effects with far-reaching health implications. In addition, they risk developing an unhealthy dependence on analgesics, a slippery slope to full-blown addiction. Luckily, with QC Kinetix (Wilmington) regenerative medicine, such individuals can begin weaning themselves off pain medications after the first few sessions.

Describing their experience at QC Kinetix (Wilmington), one impressed patient said, "I am a very anti-doctor person and, even though I was attended to by one, it has been a completely different atmosphere. I am on my third treatment, and after the first, I had much improvement in mobility and less pain. The second treatment was a little more intense than the first, but still no downtime and right back to work. After a couple of days, I can confirm full mobility and zero pain!"

Visit QC Kinetix (Wilmington) at 1410 Commonwealth Dr, Suite 100, Wilmington, NC, 28403, US, for a free consultation or to know more about their sports medicine and back pain treatment. Patients can learn more about their Wilmington office by visiting their website. Alternatively, they can contact one of their representatives via phone at (910) 378-9909 for queries.

Media Contact

QC Kinetix (Wilmington)

Scott Hoots

(910) 378-9909

1410 Commonwealth Dr, Suite 100

Wilmington

NC

28403

US

Wilmington, NC

Continue reading here:
QC Kinetix (Wilmington) is the Go-to Regenerative Medicine Clinic for Back Pain and Sports Injury Treatment - Yahoo Finance

Posted in Regenerative Medicine | Comments Off on QC Kinetix (Wilmington) is the Go-to Regenerative Medicine Clinic for Back Pain and Sports Injury Treatment – Yahoo Finance

Page 10«..9101112..2030..»